Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2021
April 26, 2021 at 09:44 am
Share
Tiansheng Pharmaceutical Group Co., Ltd. announced earnings results for the fourth quarter ended March 31, 2021. For the fourth quarter, the company announced total revenue was CNY 334.030 million compared to CNY 292.064 million a year ago. Operating loss was CNY 24.773 million compared to CNY 8.296 million a year ago. Net loss was CNY 25.296 million compared to CNY 7.821 million a year ago. Basic loss per share from continuing operations was CNY 0.0795 compared to CNY 0.0246 a year ago. For the full year, total revenue was CNY 1,202.746 million compared to CNY 1,679.540 million a year ago. Operating loss was CNY 500.342 million compared to CNY 221.649 million a year ago. Net loss was CNY 496.729 million compared to CNY 223.979 million a year ago. Basic loss per share from continuing operations was CNY 1.5432 compared to CNY 0.7008 a year ago.
Tiansheng Pharmaceutical Group Co LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company's main products include pediatric lung cough particles, erythromycin enteric-coated capsules, silver ginseng Tongluo capsules, Salvia granules, Shugan Yi spleen granules, compound Ganoderma lucidum granules, Xiangdan injection, Injection, Qi and Diabetes tablets, liver capsule, Ling Jing capsule, lungs of nuclear paste, Shen Qi Yi lung pill, among others. The Company mainly distributes its products within domestic market.